Table 5. Percentage of patients who required dose adjustments or withdrew from crizotinib therapy.

Study	Number of patients on crizotinib therapy	Percentage of patients who had to undergo dose adjustments due to adverse effects (temporarily withheld, reduced)	Percentage of patients who permanently withdrew from crizotinib therapy due to adverse effects
Solomon et al. 2014 [11]	171	14	12
Peters et al. 2017 [12]	151	46	13
Camidge et al. 2018 [13]	138	21	9
Del Valle and Chang 2019 [14]	22	27.3	13.6
Mohieldin et al. 2018 [15]	38	15.8	-
Kapoor et al. 2022 [16]	188	-	2.7
Liu et al. 2019 [17]	104	1.92	0.96
Rosa et al. 2022 [18]	91	42.8	11.4
Ueno et al. 2019 [19]	2028	38.4	26